CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

iohexol

Trade name: Omnipaque

Small moleculeapproved

Approved

Dec 26, 1985

Iohexol is a nonionic, water-soluble radiographic contrast medium. Organic iodine compounds block x-rays as they pass through the body, thereby allowing body structures containing iodine to be delineated in contrast to those structures that do not contain iodine. It is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Drugs which lower seizure threshold, especially phenothiazine derivatives including those used for their antihistaminic or antinauseant properties, are not recommended for use with Iohexol. Others include monoamine oxidase (MAO) inhibitors, tricyclic antidepressants, CNS stimulants, psychoactive drugs described as analeptics, major tranquilizers, or antipsychotic drugs. The most frequently reported adverse reactions are headache, mild to moderate pain including backache, neckache and stiffness, nausea, and vomiting. — NCATS

Clinical trial activity

56 trials · 57 clinical orgs · 3 marketing orgs

Phase 1
19
Phase 2
10
Phase 3
4
Phase 4
14

Earliest trial started Aug 1, 2007 (NCT00478556)

Timeline

1980s

  1. Dec 26, 1985

    General Electric — Earliest FDA Approval

  2. Dec 26, 1985

    General Electric — NDA Secondary Org

  3. Dec 26, 1985

    General Electric — NDA Organization

2010s

  1. Jan 1, 2010

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2013

    Earliest Phase 3 Sponsor(trial)

  3. Mar 26, 2015

    Interpharma Praha As — NDA Secondary Org

  4. Jan 1, 2016

    Earliest Phase 2 Sponsor(trial)

2020s

  1. Nov 13, 2025

    Amneal Pharmaceuticals — Marketing Organization

Indications

Approved for

Studied for

Mechanism of action

  • Unspecified targetOTHER

    Diagnostic agent

  • contrast mediumRadiopaque

    contrast medium radiopaque

Approval history

  • approvedDec 26, 1985

Chemistry & pharmacology

Loading structure…

SMILES

CC(=O)N(CC(O)CO)C1=C(I)C(C(=O)NCC(O)CO)=C(I)C(C(=O)NCC(O)CO)=C1I
Mol. weight
821.1379 g/mol
Lipinski Ro5
2 violation(s)
Rule of 3
No
Chirality
Racemic Mixture
Inorganic
No
Polymer
No
Delivery
Oral, Parenteral, Topical
Availability
Prescription Only

Oral

Yes

Parenteral

Yes

Topical

Yes

Black box warning

Sources

Also known as

  • exypaque
  • exypaque
  • iohexol
  • iohexol
  • iohexol
  • iohexol
  • iohexol
  • iohexol
  • iohexol
  • iohexol
  • iohexol
  • iohexol
  • iohexolum
  • iohexolum
  • n,n'-bis(2,3-dihydroxypropyl)-5-(n-(2,3-dihydroxypropyl)acetamido)-2,4,6-triiodoisophthalamide
  • n,n'-bis(2,3-dihydroxypropyl)-5-(n-(2,3-dihydroxypropyl)acetamido)-2,4,6-triiodoisophthalamide
  • omnipaque
  • omnipaque
  • omnipaque
  • omnipaque
  • omnipaque 140
  • omnipaque 180
  • omnipaque 180
  • omnipaque 210
  • omnipaque 210
  • omnipaque 240
  • omnipaque 240
  • omnipaque 300
  • omnipaque 350
  • omnipaque 70
  • omnipaque 70
  • win-39424
  • win-39424

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07246265N/AJan 31, 2026University Hospital, Tours
NCT07174440N/ASep 15, 2025Case Western Reserve University
NCT07042698N/AJul 15, 2025Assistance Publique - Hôpitaux de Paris
NCT06820320Phase 2Feb 15, 2025Chinese Academy of Medical Sciences
NCT06709521Phase 4Dec 3, 2024National Institute of Allergy and Infectious Diseases (NIAID)
NCT06259422N/AJun 1, 2024University of Groningen
NCT05967117Phase 4Nov 24, 2023Catholic University of Korea, Taejoon Pharm Co., Ltd.
NCT05758701Phase 4Sep 19, 2023University of Maryland
NCT05754749Early Phase 1 (Phase 1)Mar 13, 2023University of North Carolina at Chapel Hill
NCT05580250Phase 1Nov 21, 2022Eli Lilly
NCT05615467Phase 1Nov 15, 2022Eli Lilly
NCT05136963Phase 1Jun 30, 2022University of Lyon
NCT05065372Phase 1Jan 1, 2022National Heart, Lung, and Blood Institute (NHLBI), University of Colorado, Denver
NCT05065073Phase 4Sep 30, 2021Minneapolis Heart Institute
NCT04649229Phase 4Feb 28, 2021Yale University
NCT04627831Phase 2Dec 31, 2020Ligand Pharmaceuticals
NCT04504331Phase 1Oct 13, 2020National Cancer Institute (NCI), QED Therapeutics, Inc., Stanford University
NCT04742816Phase 4Sep 17, 2020University of California, San Diego
NCT04776486N/ASep 3, 2020Assistance Publique - Hôpitaux de Paris, University of Paris
NCT03997370N/AFeb 14, 2020National Cancer Institute (NCI), NRG Oncology
Showing 20 of 56 trials
Page 1 / 3

Organizations

Research & Development (57)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Eli LillyFor profit5512016
University of Colorado, DenverAcademic/Hospital4422018
General ElectricFor profit3122007
MediBeaconFor profit3322013
University of ColoradoAcademic/Hospital3012018
University of LyonAcademic/Hospital3332011
Assistance Publique - Hôpitaux de ParisAcademic/Hospital2212020
Ligand PharmaceuticalsFor profit2122019
National Cancer Institute (NCI)Government2022020
Stanford UniversityAcademic/Hospital2222010
University of MarylandAcademic/Hospital2122013
University of North Carolina at Chapel HillAcademic/Hospital2212019
AstraZenecaFor profit1012018
BayerFor profit1012019
Case Western Reserve UniversityAcademic/Hospital1112025
Catholic University of KoreaAcademic/Hospital1112023
Centro Cardiológico del Caribe, ColumbiaAcademic/Hospital1112013
Chinese Academy of Medical SciencesAcademic/Hospital1112025
Columbia UniversityAcademic/Hospital1112019
CyDex PharmaceuticalsFor profit1112019
57 organizations
Page 1 / 3

Marketing (4)

OrganizationOrg typeRelationshipDate
Amneal PharmaceuticalsFor profitMKTGNov 13, 2025
General ElectricFor profitNDA2Dec 26, 1985
General ElectricFor profitNDADec 26, 1985
Interpharma Praha AsFor profitNDA2Mar 26, 2015